• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Aethlon Medical Inc.

    11/15/24 4:40:55 PM ET
    $AEMD
    Medical/Dental Instruments
    Health Care
    Get the next $AEMD alert in real time by email
    S-8 1 aethlon_s8.htm S-8

    As filed with the Securities and Exchange Commission on November 15, 2024

     

    Registration No. 333-

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

    ____________

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

    ____________

     

    Aethlon Medical, Inc.

    (Exact name of registrant as specified in its charter)

    ____________

     

    Nevada   13-3632859
    (State or other jurisdiction of incorporation)   (I.R.S. Employer Identification No.)

     

    11555 Sorrento Valley Road, Suite 203

    San Diego, California 92121

    (Address of principal executive offices) (Zip Code)

    ____________

     

    Aethlon Medical, Inc. 2020 Equity Incentive Plan

    (Full title of the plan)

    ____________

     

    James B. Frakes

    Chief Executive Officer and Chief Financial Officer

    Aethlon Medical, Inc.

    11555 Sorrento Valley Road, Suite 203

    San Diego, California 92121

    (619) 941-0360

    (Name, address, and telephone number, including area code, of agent for service)

    ____________

     

    Copies to:

     

    Dennis J. Doucette, Esq.

    Procopio, Cory, Hargreaves & Savitch LLP

    12544 High Bluff Drive, Suite 400

    San Diego, CA 92130

    (858) 720-6300

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated Filer ☐ Accelerated Filer ☐
    Non-accelerated Filer ☒ Smaller reporting company ☒
        Emerging Growth Company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act ☐

     

     

     

       

     

     

    REGISTRATION OF ADDITIONAL SHARES PURSUANT TO GENERAL INSTRUCTION E

     

    Pursuant to General Instruction E of Form S-8, Aethlon Medical, Inc. (the “Company”) is filing this Registration Statement on Form S-8 (this “Registration Statement”) to register an additional 3,000,000 shares of Company common stock, par value $0.001 per share (“Common Stock”), for issuance under the Company’s 2020 Equity Incentive Plan (the “Original Plan”), as amended on September 15, 2022 (the “First Amendment”) and September 27, 2024 (the “Second Amendment,” and together with the Original Plan and the First Amendment, the “2020 Plan”). Such additional shares of Common Stock were added to the 2020 Plan pursuant to the Second Amendment and are in addition to the 364,256 shares of Common Stock (as adjusted for the Reverse Stock Split, as defined below) issuable pursuant to the 2020 Plan registered on the Company’s Registration Statements on Form S-8 filed with the Securities and Exchange Commission (the “Commission”) on September 15, 2020 (Commission File No. 333-248820) and September 19, 2022 (Commission File No. 333-267504), the contents of which are hereby incorporated by reference into this Registration Statement, except to the extent supplemented, amended or superseded by the information set forth in this Registration Statement or by any subsequently filed document.

     

    On October 4, 2023, the Company effected a one-for-ten reverse stock split of the Company’s issued and outstanding shares of Common Stock (the “Reverse Stock Split”). As a result of the Reverse Stock Split, every ten shares of Common Stock issued and outstanding as of 5:00 p.m. Eastern Time on October 4, 2023 were combined into one share of Common Stock. The number of shares issuable pursuant to 2020 Plan were also adjusted proportionally as a result of the Reverse Stock Split.

     

     

     

     2 

     

     

    PART II

    INFORMATION REQUIRED IN REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents, which have been filed by the Company with the Commission pursuant to the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are incorporated herein by reference:

     

    ·The Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2024, filed with the Commission on June 27, 2024, and Amendment No. 1 to the Company’s Annual Report on Form 10-K, filed with the Commission on August 15, 2024;
      
    ·The Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, filed with the Commission on August 14, 2024;
      
     ·The Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, filed with the Commission on November 13, 2024;
       
    ·The Company’s Current Reports on Form 8-K, filed with the Commission on April 25, 2024, May 10, 2024, May 17, 2024, May 24, 2024, July 3, 2024, August 12, 2024, September 19, 2024, October 2, 2024; October 3, 2024, and November 12, 2024; and
      
    ·The description of the Company’s Common Stock contained in the Company’s Registration Statement on Form 8-A, filed by the Company with the Commission under Section 12(b) of the Exchange Act, on July 8, 2015, including any amendments or reports filed for the purpose of updating such description, including Exhibit 4.16 to the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2020, filed with the Commission on June 25, 2020.

     

    All reports and other documents filed by the Company pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items, after the date of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of filing such reports and documents.

     

    Any statement contained in a document incorporated by, or deemed incorporated by reference herein, shall be deemed to be modified or superseded for purposes of this registration statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.

     

    Item 8Exhibits

     

    (d)       Exhibits

     

            Incorporation by Reference
    Exhibit Number   Exhibit Description   Form   Filing Date   Exhibit   Filed Herewith
    4.1   Articles of Incorporation, as amended.   8-K   September 19, 2022   3.1    
    4.2   Amended and Restated Bylaws of the Company.   8-K   September 12, 2019   3.1    
    5.1   Opinion of Procopio, Cory, Hargreaves & Savitch LLP.               X
    23.1   Consent of Baker Tilly US, LLP, independent registered public accounting firm.               X
    23.2   Consent of Procopio, Cory, Hargreaves & Savitch LLP (incorporated by reference to Exhibit 5.1 to this Registration Statement on Form S-8).               X
    24.1   Power of Attorney (included on the signature page hereto)               X
    99.1   Aethlon Medical, Inc. 2020 Equity Incentive Plan, as amended to date, Form of Restricted Stock Grant, Form of Option Grant and Agreement.   8-K    October 2, 2024   10.1    
    107   Filing Fee Table               X

     

     

     3 

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on November 15, 2024.

     

      Aethlon Medical, Inc.
       
      By: /s/ James B. Frakes
      James B. Frakes
      Chief Executive Officer and Chief Financial Officer

     

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints James B. Frakes as the undersigned’s true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution for such person and in such person’s name, place and stead, in any and all capacities, to file and sign any and all amendments to this Registration Statement, including any and all post-effective amendments, and to file such amendments thereto, with exhibits thereto and other documents in connection therewith, with the Commission, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitutes, may lawfully do or cause to be done by virtue hereof.

     

    ***

     

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed below by the following persons in the capacities and on the dates indicated.

     

    Signature   Title   Date
             
    /s/ James B. Frakes  

    Chief Executive Officer, Chief Financial Officer and Director

    (Principal Executive, Financial and Accounting Officer)

      November 15, 2024
    James B. Frakes      
             
    /s/ Edward G. Broenniman   Chairman of the Board, Director   November 15, 2024
    Edward G. Broenniman      
             
    /s/ Chetan Shah, MD  

    Director

     

      November 15, 2024
    Chetan Shah, MD      
             
    /s/ Angela Rossetti   Director   November 15, 2024
    Angela Rossetti      
             
    /s/ Nicolas Gikakis   Director   November 15, 2024
    Nicolas Gikakis        

     

     

     

     4 

     

    Get the next $AEMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AEMD

    DatePrice TargetRatingAnalyst
    7/7/2025$1.50Neutral
    H.C. Wainwright
    6/25/2021$5.00 → $9.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $AEMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Shah Chetan covered exercise/tax liability with 179 shares, decreasing direct ownership by 7% to 2,356 units (SEC Form 4)

    4 - AETHLON MEDICAL INC (0000882291) (Issuer)

    1/2/26 6:43:21 PM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    Director Gikakis Nicolas covered exercise/tax liability with 179 shares, decreasing direct ownership by 7% to 2,357 units (SEC Form 4)

    4 - AETHLON MEDICAL INC (0000882291) (Issuer)

    1/2/26 6:42:37 PM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    Director Broenniman Edward G covered exercise/tax liability with 89 shares, decreasing direct ownership by 3% to 2,807 units (SEC Form 4)

    4 - AETHLON MEDICAL INC (0000882291) (Issuer)

    1/2/26 6:41:25 PM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    $AEMD
    SEC Filings

    View All

    SEC Form 10-Q filed by Aethlon Medical Inc.

    10-Q - AETHLON MEDICAL INC (0000882291) (Filer)

    2/12/26 5:10:41 PM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    Aethlon Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - AETHLON MEDICAL INC (0000882291) (Filer)

    2/12/26 4:15:44 PM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    SEC Form DEFA14A filed by Aethlon Medical Inc.

    DEFA14A - AETHLON MEDICAL INC (0000882291) (Filer)

    1/27/26 4:15:26 PM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    $AEMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aethlon Medical Announces Fiscal Q3 2026 Financial Results and Corporate Update

    Clinical and research programs continue to advance, supported by year-to-date cost efficiencies Conference Call Today at 4:30 p.m. ET SAN DIEGO, Feb. 12, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal third quarter ended December 31, 2025, and provided an update on recent developments.  Key Highlights Maintained Nasdaq Listing: Continued compliance with Nasdaq listing requirements, with all prior compliance matters remaining resolved. Clinical Progress: Cohort 2 of the Australian oncology tr

    2/12/26 4:15:00 PM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 12, 2026

    SAN DIEGO, Feb. 4, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal third quarter ended December 31, 2025, at 4:15 p.m. ET on Thursday, February 12, 2026. Management will host a conference call on Thursday, February 12, 2026, at 4:30 p.m. ET to review financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session. Interested parties can register for the conference call by navigating to https://dpregister.com/sreg/10206585/1034

    2/4/26 8:01:00 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    Aethlon Medical Announces Pricing of a Private Placement and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $3.3 Million

    SAN DIEGO, Dec. 5, 2025 /PRNewswire/ -- Aethlon Medical, Inc. ("Aethlon" or the "Company") (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 595,897 shares of common stock (or pre-funded warrants in-lieu thereof), together with warrants to purchase up to an aggregate 1,042,820 shares of common stock, in a private placement priced at-the-market under Nasdaq rules. The combined effective offering price for each share of common stock (or pre-funded warrant in-lieu thereof) and accompanying wa

    12/5/25 9:15:00 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    $AEMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on Aethlon Medical with a new price target

    H.C. Wainwright resumed coverage of Aethlon Medical with a rating of Neutral and set a new price target of $1.50

    7/7/25 8:15:50 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    HC Wainwright & Co. reiterated coverage on Aethlon Medical with a new price target

    HC Wainwright & Co. reiterated coverage of Aethlon Medical with a rating of Buy and set a new price target of $9.00 from $5.00 previously

    6/25/21 6:10:29 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    HC Wainwright & Co. initiated coverage on Aethlon Medical with a new price target

    HC Wainwright & Co. initiated coverage of Aethlon Medical with a rating of Buy and set a new price target of $5.00

    6/1/21 8:48:18 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    $AEMD
    Financials

    Live finance-specific insights

    View All

    Aethlon Medical Announces Fiscal Q3 2026 Financial Results and Corporate Update

    Clinical and research programs continue to advance, supported by year-to-date cost efficiencies Conference Call Today at 4:30 p.m. ET SAN DIEGO, Feb. 12, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal third quarter ended December 31, 2025, and provided an update on recent developments.  Key Highlights Maintained Nasdaq Listing: Continued compliance with Nasdaq listing requirements, with all prior compliance matters remaining resolved. Clinical Progress: Cohort 2 of the Australian oncology tr

    2/12/26 4:15:00 PM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 12, 2026

    SAN DIEGO, Feb. 4, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal third quarter ended December 31, 2025, at 4:15 p.m. ET on Thursday, February 12, 2026. Management will host a conference call on Thursday, February 12, 2026, at 4:30 p.m. ET to review financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session. Interested parties can register for the conference call by navigating to https://dpregister.com/sreg/10206585/1034

    2/4/26 8:01:00 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    Aethlon Medical Announces Fiscal Q2 2025 Financial Results and Corporate Update

    Clinical and research progress continues alongside substantial cost reductions. Conference Call Today at 4:30 p.m. ET SAN DIEGO, Nov. 12, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal second quarter ended September 30, 2025, and provided an update on recent developments.  Key Highlights Maintained Nasdaq Listing: Compliance matters resolved, Aethlon remains in good standing with Nasdaq.Clinical Progress: Recruitment underway for Cohort 2 of the Australian oncology trial under amended protoc

    11/12/25 4:15:00 PM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    $AEMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Aethlon Medical, Inc. (Amendment)

    SC 13G/A - AETHLON MEDICAL INC (0000882291) (Subject)

    1/13/22 10:30:14 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Aethlon Medical, Inc.

    SC 13G - AETHLON MEDICAL INC (0000882291) (Subject)

    6/15/21 10:01:32 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - AETHLON MEDICAL INC (0000882291) (Subject)

    2/22/21 9:53:48 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care